IYH iShares U.S. Healthcare ETF
Company Analysis
Latest News
CVS Reverses Course to Cover Eli Lilly’s Zepbound, Challenging Novo Nordisk
CVS Caremark will begin covering Eli Lilly’s weight-loss medication, Zepbound, starting October 1, 2026. This decision marks a significant reversal for the...
🟢 iShares U.S. Healthcare ETF is trading 3.1% up today as investors rotate into defensive healthcare
iShares U.S. Healthcare ETF is trading 3.1% up as capital rotates out of volatile tech and AI-linked growth stocks into more defensive sectors like...
Johnson & Johnson’s ERLEADA Cuts Cancer Risk 20%, Setting New Treatment Standard
Johnson & Johnson released final Phase 3 PROTEUS study results for its prostate cancer drug, ERLEADA (apalutamide). The study focused on patients with...
J&J ERLEADA Cuts Prostate Cancer Risk by 20%, Shifting Treatment Standards
Johnson & Johnson announced final Phase 3 PROTEUS study results for ERLEADA (apalutamide). The drug significantly improved outcomes for patients with high-risk...
Johnson & Johnson’s Erleada cuts prostate cancer metastasis risk by 20%
Johnson & Johnson reported that ERLEADA (apalutamide) combined with hormone therapy reduced the risk of metastasis or death by 20% in high-risk prostate cancer...
Eli Lilly surges on Retatrutide data, showing surgery-like weight loss
Eli Lilly and Company shares surged on May 30, 2026. The company released breakthrough clinical trial data for its next-generation obesity drug,...
Pfizer strikes $10 billion Innovent deal, securing 12 Chinese cancer treatments
Pfizer partnered with Chinese drugmaker Innovent Biologics on a strategic alliance worth over $10 billion. The collaboration aims to develop up to 12...
Bristol Myers Squibb Cuts Multiple Myeloma Risk 52%, Validating New Drug Class
Bristol Myers Squibb announced positive results from the Phase 3 SUCCESSOR-2 trial for mezigdomide. The study evaluated the treatment for patients with...
Johnson & Johnson Wins FDA Approval for TREMFYA to Prevent Joint Damage
Johnson & Johnson received FDA approval for a supplemental Biologics License Application for its drug TREMFYA (guselkumab). The expanded label includes...
Eli Lilly Hits Record High, Securing Key CVS Obesity Drug Coverage
CVS Caremark will add Eli Lilly’s new oral obesity pill, Foundayo, to its formulary. The pharmacy benefit manager (PBM) also restored coverage for the...
Eli Lilly bets $3.8 billion on vaccines, using obesity drug cash
Eli Lilly agreed to acquire Curevo, LimmaTech Biologics, and Vaccine Company for a potential $3.83 billion. The company is using significant cash flow from its...
Eli Lilly buys three vaccine firms for $4B, diversifying beyond Mounjaro success
Eli Lilly signed agreements to acquire three private vaccine companies for nearly $4 billion. The deal includes the acquisition of Curevo, LimmaTech...